


## “Reversine” and Its 2-Substituted Adenine Derivatives as Potent and Selective A Adenosine Receptor Antagonists

Melissa Perreira, Jian-kang Jiang, Athena M. Klutz, Zhan-Guo Gao, Asher Shainberg, Changrui Lu, Craig J. Thomas, and Kenneth A. Jacobson

*J. Med. Chem.*, **2005**, 48 (15), 4910-4918 • DOI: 10.1021/jm050221l • Publication Date (Web): 06 July 2005

Downloaded from <http://pubs.acs.org> on March 28, 2009



R = cycloalkyl  
R' = phenyl or substituted phenyl  
R'' = H, methyl  
X = NH, O, S

### More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Links to the 2 articles that cite this article, as of the time of this article download
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

[View the Full Text HTML](#)



# “Reversine” and Its 2-Substituted Adenine Derivatives as Potent and Selective A<sub>3</sub> Adenosine Receptor Antagonists

Melissa Perreira,<sup>†,‡</sup> Jian-kang Jiang,<sup>†,‡</sup> Athena M. Klutz,<sup>§</sup> Zhan-Guo Gao,<sup>§</sup> Asher Shainberg,<sup>§,||</sup> Changrui Lu,<sup>§</sup> Craig J. Thomas,<sup>†</sup> and Kenneth A. Jacobson<sup>\*,†,§</sup>

Chemical Biology Core Facility, and Molecular Recognition Section, Laboratory of Biological Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, and Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 52900, Israel

Received March 9, 2005


The dedifferentiation agent “reversine” [2-(4-morpholinoanilino)-N<sup>6</sup>-cyclohexyladenine **2**] was found to be a moderately potent antagonist for the human A<sub>3</sub> adenosine receptor (AR) with a K<sub>i</sub> value of 0.66 μM. This result prompted an exploration of the structure–activity relationship of related derivatives, synthesized via sequential substitution of 6-chloro-2-fluoropurine with selected nucleophiles. Optimization of substituents at these two positions identified 2-(phenylamino)-N<sup>6</sup>-cyclohexyladenine (**12**), 2-(phenylamino)-N<sup>6</sup>-cycloheptyladenine (**19**), and 2-phenylamino-N<sup>6</sup>-endo-norbornyladenine (**21**) as potent A<sub>3</sub> AR ligands with K<sub>i</sub> values of 51, 42, and 37 nM, respectively, with 30–200-fold selectivity in comparison to A<sub>1</sub> and A<sub>2A</sub> ARs. The most selective A<sub>3</sub> AR antagonist (>200-fold) was 2-(phenyloxy)-N<sup>6</sup>-cyclohexyladenine (**22**). 9-Methylation of **12**, but not **19**, was well-tolerated in A<sub>3</sub> AR binding. Extension of the 2-phenylamino group to 2-benzyl- and 2-(2-phenylethylamino) reduced affinity. In the series of 2-(phenylamino), 2-(phenyloxy), and 2-(phenylthio) substitutions, the order of affinity at the A<sub>3</sub> AR was oxy ≥ amino > thio. Selected derivatives, including reversine (K<sub>B</sub> value of 466 nM via Schild analysis), competitively antagonized the functional effects of a selective A<sub>3</sub> AR agonist, i.e., inhibition of forskolin-stimulated cAMP production in stably transfected Chinese hamster ovary (CHO) cells. These results are in agreement with other studies suggesting the presence of a lipophilic pocket in the AR binding site that is filled by moderately sized cycloalkyl rings at the N<sup>6</sup> position of both adenine and adenosine derivatives. Thus, the compound series reported herein comprise an important new series of selective A<sub>3</sub> AR antagonists. We were unable to reproduce the dedifferentiation effect of reversine, previously reported, or to demonstrate any connection between A<sub>3</sub> AR antagonist effects and dedifferentiation.

## Introduction

The A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> adenosine receptors (ARs) are G-protein-coupled receptors that are specifically distributed throughout various tissues and cell types of the human body.<sup>1</sup> The ubiquitous nature of the natural ligand, adenosine, has prompted countless studies aimed to delineate the extent to which each subtype of the receptor could be selectively modulated and if such a modulation could be exploited for some therapeutic advantage. Over the past decade, it has become apparent that control of the four AR subtypes has a wide-ranging impact on stroke and other ischemic conditions, as well as inflammation, neurodegenerative diseases, diabetes, sleep regulation, and other therapeutic fronts.<sup>2</sup>

The structure–activity relationships (SAR) of adenosine derivatives as selective agonists at three of the four AR subtypes (except for A<sub>2B</sub>) is well-developed.<sup>4–8</sup> Among AR antagonists, several classes of small non-nucleoside heterocycles, including xanthines, deazaadenines, pyrazolopyrimidines, and adenines, have

**Chart 1.** Structures of Selected Adenine Derivatives Reported as AR Antagonists (1a–c) and Reversine (2)



varying degrees of potency and receptor subtype selectivity.<sup>1,9</sup> Various 9-alkyladenine derivatives have displayed high selectivity for the A<sub>1</sub> AR and more modest selectivity for A<sub>2A</sub> and A<sub>3</sub> ARs.<sup>10–13</sup> For example, 8-[(N-methylisopropyl)amino]-N<sup>6</sup>-(endo-2'-(endo-5'-hydroxy)-norbornyl)-9-methyladenine (WRC-0571, **1a**) (Chart 1) displayed a K<sub>i</sub> value of 1.7 nM at the human A<sub>1</sub> AR.<sup>14</sup> Compound **1b** was 10-fold more potent at antagonizing

\* Corresponding author. Tel: 301-496-9024. Fax: 301-480-8422. E-mail: kajacobs@helix.nih.gov.

<sup>†</sup> Chemical Biology Core Facility, NIH.

<sup>‡</sup> Contributed equally to this work.

<sup>§</sup> Molecular Recognition Section, Laboratory of Biological Chemistry, NIH.

<sup>||</sup> Bar-Ilan University.

the A<sub>2A</sub> AR in guinea pig coronary artery than a putative A<sub>2B</sub> AR in the aorta.<sup>15</sup> An attempt to convert known A<sub>3</sub> AR agonists, such as Cl-IB-MECA [2-chloro-*N*<sup>6</sup>-(3-iodobenzyl)-5'-(*N*-methylcarboxamido)adenosine], into selective antagonists at the same subtype through truncation of the ribose moiety in stages greatly reduced receptor affinity.<sup>13</sup> A series of 8-substituted adenine derivatives, such as 9-ethyl-8-(phenylethynyl)-9*H*-adenine **1c**, displayed selectivity as antagonists of the human A<sub>3</sub> AR.<sup>11</sup> A<sub>3</sub> AR antagonists are of interest as antiglaucoma agents and in inflammatory diseases.<sup>32–34</sup>


Adenine derivatives are also important pharmacological probes of other biochemical processes such as kinase inhibition,<sup>16</sup> and the AR affinity of such derivatives has not been fully explored. An 9-alkyladenine derivative, SQ22536, that inhibits another signaling enzyme, adenylyl cyclase, was also shown to antagonize the A<sub>1</sub> AR.<sup>17</sup> Recently, Chen et al. reported that “reversine” [2-(4-morpholinoanilino)-*N*<sup>6</sup>-cyclohexyladenine, **2**] (Chart 1), selected from a large chemical library, stimulated the dedifferentiation of lineage-committed cells (myoblasts) back to progenitor cells, which were capable of being redirected via osteogenic-inducing agents or adipogenic-inducing agents into osteoblasts or adipocytes, respectively.<sup>18</sup> This remarkable discovery has vast consequences throughout biological and medical research. The mechanism by which this extraordinary transformation takes place is as yet unknown and subject to speculation and investigation. This project will no doubt be a formidable undertaking, given the breadth of the cellular landscape and the complexity of the phenotypic response. We noted the similarity of the substitution pattern of **2** in relation to various known AR antagonists and considered that, while not knowing the significance of AR modulation on the cell cycle and/or dedifferentiation, reversine might selectively bind at one or more of the ARs.

Following the protocols set forth by Ding et al., we synthesized several 2,6-disubstituted purine analogues including reversine (**2**).<sup>19</sup> Our initial results showed that **2** bound with moderate affinity to the A<sub>3</sub> AR. Our selection of derivatives was motivated by a desire to initially explore the SAR for this series of compounds at the ARs rather than to expand on the theme of dedifferentiation. Accordingly, we diverged from the parent structure in several fundamental ways, i.e., the size of the cycloalkyl ring at *N*<sup>6</sup>, the substitution pattern of the aromatic ring at C2, heteroatom substitution of the 2-amino group, and methylation at the 9 position.

## Results and Discussion


**Chemical Synthesis.** The preparation of **2** and its analogues (**4–24**) was achieved via the established protocols of Ding et al. (Scheme 1).<sup>19</sup> Substitution of 6-chloro-2-fluoropurine (**3**) with a series of amines, including ethylamine and several cyclic amines of varying sizes from cyclopropyl to 2-*endo*-norbornyl, was accomplished in *n*-butanol with Hunig's base at 80 °C over 24 h. Following solvent removal, the crude reaction mixture was treated with an excess of a second series of amines, including ethylamine and several amines with various aromatic groups (see Table 2), phenol, or thiophenol, in ethanol and heated in a sealed tube at 110 °C for 48 h. Following flash chromatography the

### Scheme 1. Synthesis of 2,6-Disubstituted Purine Derivatives<sup>a</sup>



<sup>a</sup> Reagents and conditions: (i) *R*-NH<sub>2</sub> (0.9 equiv.), Hunig's base, *n*-BuOH, 80 °C, 24 h; (ii) *R*'-NH<sub>2</sub>, *R*'-OH, or *R*'-SH (2 equiv), EtOH, 110 °C, 48 h; (iii) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF 0 °C 1–2 h

**Table 1.** Binding Affinities of *N*<sup>6</sup>-Substituted Derivatives of 2-(4-Morpholinoanilino)adenine at Human A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> ARs Expressed in CHO Cells<sup>a</sup>




compd	R <sub>1</sub>	K <sub>i</sub> (hA <sub>3</sub> AR) (μM) <sup>a</sup>	K <sub>i</sub> (hA <sub>1</sub> AR) (μM) or % inhibn at 10 μM	K <sub>i</sub> (hA <sub>2A</sub> AR) (μM) or % inhibn at 10 μM
4	ethyl	1.53 ± 0.47	23%	16%
5	cyclopropyl	1.87 ± 0.89	22%	25%
6	cyclobutyl	1.81 ± 0.50	29%	18%
7	cyclopentyl	1.39 ± 0.48	22%	20%
<b>2<sup>b</sup></b>	cyclohexyl (reversine)	0.66 ± 0.14	>10 (36%)	>10 (30%)
8	cycloheptyl	0.42 ± 0.17	6%	38%
9	cyclooctyl	2.77 ± 0.83	0%	17%
10	2- <i>endo</i> -norbornyl	0.122 ± 0.010	34%	39%

<sup>a</sup> All A<sub>3</sub>AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding one of the human adenosine receptor. Binding at human A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub>ARs in this study was carried out as described in the methods using [<sup>3</sup>H]-DPCPX, [<sup>3</sup>H]ZM241,385 or [<sup>125</sup>I]-AB-MECA as radioligand. Values from the present study are expressed as K<sub>i</sub> values (mean ± SEM, *n* = 3) or as percent displacement of radioligand. <sup>b</sup> Demonstrated to be antagonist of the human A<sub>3</sub> AR.

yields of the purified products ranged typically from 30 to 60% for the two-step procedure. We noted that the substitution of 2,6-dichloropurine resulted in the same transformation; however, the use of 6-chloro-2-fluoropurine was more facile and provided a convenient method to ensure that the correct 2,6-substitution pattern was achieved via mass analysis of the fluorinated intermediate. We also noted the success of microwave-assisted organic synthesis in the facile preparation of similar 2,6-disubstituted purine analogues (data not shown). Selected analogues were methylated at the *N*<sup>9</sup> position in quantitative yield via treatment with methyl iodide in basic DMF at 0 °C over 1–2 h.

**Biological Characterization.** Binding affinity at the human A<sub>3</sub> AR and in selected cases the rat A<sub>3</sub> AR was studied using the radioiodinated agonist [<sup>125</sup>I]-*N*<sup>6</sup>-(4-amino-3-iodobenzyl)adenosine-5'-*N*-methyluronamide (1-AB-MECA).<sup>20</sup> Binding at the human A<sub>1</sub> and A<sub>2A</sub> receptors utilized the selective antagonists [<sup>3</sup>H]-8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and [<sup>3</sup>H]-4-2-[7-amino-2-(2-furyl)-1,2,4-triazolo[1,5-*a*][1,3,5]triazin-5-yl-amino]ethylphenol (ZM241,385), respectively. Functional assays of the human A<sub>3</sub> receptor consisted of measuring inhibition of forskolin-stimulated cAMP production in intact Chinese hamster ovary (CHO) cells expressing the ARs.<sup>21</sup>

**Table 2.** Binding Affinities of 2-Substituted  $N^6$ -Cyclohexyladenine Derivatives at Human  $A_1$ ,  $A_{2A}$ , and  $A_3$  ARs Expressed in CHO Cells<sup>a</sup>

compd	$R_2$	$K_i$ ( $hA_3$ AR) $\mu M^a$	$K_i$ ( $hA_1$ AR)	$K_i$ ( $hA_{2A}$ AR)
			( $\mu M$ ) or % inhibn at 10 $\mu M$	( $\mu M$ ) or % inhibn at 10 $\mu M$
11	ethyl	$1.12 \pm 0.61$	51%	42%
12	phenyl	$0.051 \pm 0.017$	$2.73 \pm 0.58$	$1.70 \pm 0.95$
13	benzyl	$0.920 \pm 0.121$	42%	34%
14	2-phenylethyl	$1.46 \pm 0.11$	$3.17 \pm 1.02$	46%
15	2-naphthyl	$2.42 \pm 1.44$	39%	52%
16	biphenyl-1-yl	$5.40 \pm 1.00$	14%	22%
17	4-piperidinophenyl	$1.57 \pm 0.56$	16%	50%
18	4-(dimethylamino)-phenyl	$0.070 \pm 0.025$	$3.90 \pm 0.96$	$6.1 \pm 2.5$

<sup>a</sup> All  $A_3$  AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding one of the human adenosine receptors. Binding at human  $A_1$ ,  $A_{2A}$ , and  $A_3$  ARs in this study was carried out as described in the methods using [<sup>3</sup>H]-DPCPX, [<sup>3</sup>H]ZM241,385, or [<sup>125</sup>I]AB-MECA as radioligand. Values from the present study are expressed as  $K_i$  values (mean  $\pm$  SEM,  $n = 3$ ) or as a percent displacement of radioligand.

An initial screen of the dedifferentiation agent reversine (**2**) at the ARs indicated binding at the  $A_3$  AR with a  $K_i$  value of  $0.66 \mu M$ . At the  $A_1$  and  $A_{2A}$  ARs, binding was much weaker, with only 36% and 30% of radioligand binding inhibited, respectively, at  $10 \mu M$  of **2**. Following the identification of **2** as a moderately potent ligand in binding at the  $A_3$  AR, we sought to explore the SAR of related 2,6-disubstituted purines in order to enhance potency and  $A_3$  AR selectivity. Our initial notion was to individually consider the two structurally distinct moieties on the purine ring system, i.e., the  $N^6$ -cyclohexyl ring and the 2-(4-morpholino-anilino) moiety. The binding results for these two sets of analogues are displayed in Tables 1 and 2.

$N^6$ -Alkylation of both adenosine and adenine analogues is well-established as a means to increase the potency and selectivity at the ARs.<sup>4–7,10,12</sup> Clearly, as seen in Table 1, the size of the  $N^6$ -cycloalkyl ring had important consequences for binding at the  $A_3$  AR. The  $A_3$  AR affinity increased in stages upon enlarging the ring size from the cyclopropyl derivative **5** ( $K_i = 1.9 \mu M$ ) to the cycloheptyl derivative **8** ( $K_i = 0.42 \mu M$ ), strongly suggesting that a bulky hydrophobic alkyl group was favored at the  $N^6$  position. The trend appeared to be limited to cycloalkyl rings smaller than eight carbons in size, as demonstrated by a reduced tolerance for the cyclooctyl ring in **9**. The most potent 2-(4-morpholino-phenylamino)adenine derivative contained the rigid  $N^6$ -(2-*endo*-norbornyl) substituent **10** ( $K_i = 0.122 \mu M$ ).

Exploration of the moiety at the 2-NH suggested that smaller aromatic analogues were more apt to bind strongly at the  $A_3$  receptor subtype, as demonstrated by the high affinity of the 2-phenylamino analogue **12** ( $K_i = 0.051 \mu M$ ) and the 2-(4-dimethylamino)phenylamino analogue **18** ( $K_i = 0.070 \mu M$ ) (Table 2). The 2-ethylamino derivative **11** was less potent than **2** at the  $A_3$  AR. In the series of phenylamino (**12**), benzyl-

amino (**13**), and (2-phenylethyl)amino (**14**) substitutions, there was a pronounced preference for the shortest analogue **12**. In comparison to substituted phenylamino derivatives **15–18**, the unsubstituted **12** displayed the highest  $A_3$  AR affinity.

The compelling finding that 2-phenylamino analogues bound strongly at the  $A_3$  AR motivated us to further explore a series of analogues that maintained the 2-phenylamino moiety while optimizing the  $N^6$ -cycloalkyl ring (Table 3). We also replaced the 2-NH with either oxygen or sulfur as the heteroatom. The results of these analogues supported the SAR regarding ring size at the  $N^6$  position; i.e., cyclohexyl **12** and cycloheptyl **19** rings provided analogues with strong binding properties while the cyclooctyl derivative **20** showed 7–8-fold weaker affinity (Table 3). The  $N^6$ -*endo*-norbornyl analogue **21** appeared to be the most potent in the series in binding to the  $A_3$  AR. In the series of  $N^6$ -cyclohexyl derivatives having phenylamino (**12**), phenyloxy (**22**), and phenylthio (**24**) substitutions, the order of affinity at the  $A_3$  AR was oxy  $\geq$  amino  $>$  thio. This also matched the order of affinity of 2-substituted adenosine derivatives at the  $A_3$  AR, which was oxy  $>$  amino  $>$  thio.<sup>22</sup> Thus, the replacement of the NH with other heteroatoms helped to optimize the SAR for the  $A_3$  AR only when NH was replaced with O; however, the phenylthio analogue maintained a moderate affinity for the  $A_3$  AR. We further altered analogues **12** and **19** by a simple methylation based upon numerous reports describing 9-alkyl adenine derivatives as AR antagonists.<sup>11,23</sup> While 9-methylation of the  $N^6$ -cyclohexyl analogue **12** to yield **25** ( $K_i = 0.070 \mu M$ ) provided a derivative that maintained its affinity for the  $A_1$ ,  $A_{2A}$ , and  $A_3$  ARs,  $N^9$  alkylation on the cycloheptyl analogue to yield **26** ( $K_i = 0.96 \mu M$ ) was detrimental, leading to an unanticipated 23-fold loss of  $A_3$  AR affinity in comparison to **19** with no significant change in affinity at the  $A_1$  and  $A_{2A}$  ARs (Table 3).

The affinity at human  $A_1$  and  $A_{2A}$  ARs was low with most derivatives binding only weakly at  $10 \mu M$ . Various 2-phenylamino derivatives displayed measurable affinity at the  $A_1$  AR with  $K_i$  values in the range of 2–3  $\mu M$ , i.e., **12** ( $N^6$ -cyclohexyl), **19** ( $N^6$ -cycloheptyl), **21** ( $N^6$ -*endo*-norbornyl), **25** ( $N^6$ -cyclohexyl-9-methyl), and **26** ( $N^6$ -cycloheptyl-9-methyl). The following are  $K_i$  values of the same derivatives (in  $\mu M$ ) at the  $A_{2A}$  AR: **12** (1.70), **19** (4.12), **21** (7.73), **25** (1.20), and **26** (2.95). Thus, the most selective  $A_3$  AR antagonists in this study was **22**, with selectivity ratios of  $>200$  in comparison to the  $A_1$  and  $A_{2A}$  AR subtypes. The very potent compounds **12** and **21** were 54- and 60-fold selective, respectively, in comparison to the  $A_1$  AR. A comparison of  $N^6$ -cyclohexyl derivatives **12** and **22** indicated that the 2-aryloxy group was more advantageous for  $A_3$  AR selectivity than the corresponding 2-arylamino group. Thus, within this series compound **22** displayed the most favorable combination of high affinity ( $K_i$  47 nM) and selectivity for the human  $A_3$  AR.


Selected derivatives (**2**, **12**, and **18**) were tested in binding to the rat  $A_3$  AR and were shown to be inactive at  $10 \mu M$ . Therefore, the previously noted species dependence of the affinity of most known  $A_3$  AR antagonists (human  $\gg$  rat)<sup>1,7,32</sup> also applied to this series of  $A_3$  AR antagonists.



**Table 3.** Binding Affinities of 2,6-Disubstituted Adenine Derivatives at Human A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> ARs Expressed in CHO Cells<sup>a</sup>

compd <sup>b</sup>	X	Y	R <sub>1</sub>	K <sub>i</sub> (hA <sub>3</sub> AR) μM <sup>a</sup>	K <sub>i</sub> (hA <sub>1</sub> AR) (μM) or % inhibn at 10 μM	K <sub>i</sub> (hA <sub>2A</sub> AR) (μM) or % inhibn at 10 μM
12	NH	H	cyclohexyl	0.051 ± 0.017	2.73 ± 0.58	1.70 ± 0.95
19	NH	H	cycloheptyl	0.042 ± 0.010	1.72 ± 0.02	4.12 ± 0.48
20	NH	H	cyclooctyl	0.340 ± 0.016	4.47 ± 0.01	46%
21	NH	H	2-endo-norbornyl	0.037 ± 0.009	2.22 ± 0.58	7.73 ± 0.13
22	O	H	cyclohexyl	0.047 ± 0.012	26%	16%
23	O	H	2-endo-norbornyl	0.074 ± 0.007	1.47 ± 0.01	25%
24	S	H	cyclohexyl	0.134 ± 0.007	3%	14%
25	NH	methyl	cyclohexyl	0.070 ± 0.021	1.88 ± 0.01	1.20 ± 0.15
26	NH	methyl	cycloheptyl	0.96 ± 0.51	1.94 ± 0.41	2.95 ± 1.00

<sup>a</sup> All A<sub>3</sub>AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding one of the human adenosine receptor. Binding at human A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> ARs in this study was carried out as described in the methods using [<sup>3</sup>H]DPCPX, [<sup>3</sup>H]ZM241,385, or [<sup>125</sup>I]AB-MECA as radioligand. Values from the present study are expressed as K<sub>i</sub> values (mean ± SEM, n = 3) or as percent displacement of radioligand. <sup>b</sup> 12, MRS3767; 19, MRS3769; 22, MRS3777.




**Figure 1.** Schild analysis for antagonism of the human A<sub>3</sub> AR in stably transfected CHO cells by compound **2**. Cl-IB-MECA is used as a potent A<sub>3</sub> AR agonist. The experiment was performed in the presence of 10 μM rolipram. Forskolin (10 μM) was used to stimulate cyclic AMP levels. The level of cAMP corresponding to 100% was 220 ± 30 pmol mL<sup>-1</sup>.

Functional antagonism of the human A<sub>3</sub> AR by this series of adenine derivatives was demonstrated in CHO cells stably expressing the receptor. A functional assay consisting of human A<sub>3</sub> AR-mediated inhibition of forskolin-stimulated adenylyl cyclase was used. A Schild analysis of inhibition by **2** of the effects of an A<sub>3</sub> AR agonist Cl-IB-MECA at the human A<sub>3</sub> AR confirmed that this adenine derivative was a competitive antagonist with a K<sub>B</sub> value of 466 nM (Figure 1). This value was in close agreement with the K<sub>i</sub> value determined in the binding assay.

Selected compounds were examined for antagonism of the human A<sub>2B</sub> AR. As with the A<sub>3</sub> AR, the A<sub>2B</sub> AR was stably expressed in CHO cells for a standard

adenylyl cyclase assay.<sup>6</sup> 5'-(N-Ethylcarboxamido)-adenosine (NECA, 100 nM) was used as agonist, and each adenine derivative was tested at a concentration of 10 μM. Results are reported for each of the following compounds as percent inhibition of the NECA-elicited production of cAMP: **2** and **12** <10%; **21**, 31 ± 4%; **22**, 13 ± 2%; and **25**, 12 ± 3%. The adenine derivatives in the absence of agonist had no effect on cAMP levels in the A<sub>2B</sub> AR-expressing CHO cells.

We attempted to investigate whether other AR antagonists might also display the dedifferentiation effect of **2** according to the reported procedure.<sup>18</sup> However, the experiments were inconclusive since there were difficulties obtaining a definitive effect with **2**, itself, which displayed toxic effects. Similar results were obtained with compound **12** (5 μM). Mouse C2C12 myogenic cells in culture normally fuse to form myotubes. We found that exposure of the cells for 4 days to 5 μM **2** and then for 7 days to a differentiating medium, consisting of 0.1 μM dexamethasone, 50 μg/mL ascorbic acid-2-phosphate, and 10 mM β-glycerophosphate under the conditions reported,<sup>18</sup> produced extensive cell death. The remaining live cells did not proliferate, and some cells still fused to form myotubes (Figure 2B), although to a lesser degree than control cells (Figure 2A). Only a few percent of the mononucleated cells stained positive for alkaline phosphatase (not shown), which is one indicator of osteogenic differentiation,<sup>18</sup> but this staining was also obtained in the cells not treated with differentiating medium (Figure 2C). Other AR antagonists of low selectivity,<sup>1</sup> including XAC (8-[4-(carboxymethoxy)phenyl]-1,3-di-*n*-propylxanthine), CGS15943 (*N*-[9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-*c*]quinazolin-5-amine), and MRS1523 (5-propyl-2-ethyl-4-propyl-3-[(ethylsulfanyl)carbonyl]-6-phenylpyridine-5-carboxylate), each at 5 μM, were not toxic to the cells and did not show dedifferentiating effects using the same protocol.<sup>18</sup> When, immediately after treatment with **2**, the cells were transferred to medium containing 2–5% horse serum, which is a condition normally used for their differentiation (myogenesis), the cells differentiated to myotubes to a similar extent as control cells.



**Figure 2.** Micrograph of the effects of differentiating medium and AR antagonists on mouse C2C12 myogenic cells. Shown are (A) control differentiated myotubes and (B) cells after 4-day treatment with 5  $\mu\text{M}$  of the adenine derivative **2** followed by maintaining the cells for an additional 7 days in differentiating medium containing 0.1  $\mu\text{M}$  dexamethasone, 50  $\mu\text{g}/\text{mL}$  ascorbic acid-2-phosphate, and 10 mM  $\beta$ -glycerophosphate (see Experimental Section). (C) Cells treated identically to the description in B, except lacking differentiating medium. Arrows indicate cells that stained positive for alkaline phosphatase activity using a semiquantitative method. Bar in part A indicates 20  $\mu\text{m}$ .

## Discussion

It was apparent from Tables 1–3 that 2-(phenylamino)- $N^6$ -cycloadenines are capable of binding to the

AR family, in some cases with high selectivity toward the  $A_3$  subtype. Functional analysis of these compounds has demonstrated that they can produce a potent antagonistic effect at the human  $A_3$  AR. The initial SAR profile for this class of molecules suggested that among the variety of reported adenine derivatives, the 2-(phenylamino)- $N^6$ -cyclohexyl/cycloheptyl substitution pattern offered the highest affinity for binding at the  $A_3$  AR. While these adenine-based compounds demonstrated a reduced affinity compared to nucleoside-based ligands, they constitute an important advance, particularly with respect to  $A_3$  AR antagonists. A more extensive SAR study of this series, e.g. probing the effects of substitution pattern of the 2-phenylamino ring or the introduction of polar groups to increase aqueous solubility, is warranted.

More extensive SAR studies have been carried out for adenosine derivatives as agonists at the ARs than for adenine derivatives as antagonists. In general, a comparison of the SAR within these two classes provides parallels in some aspects (e.g.  $N^6$ -cycloalkyl groups at the  $A_1$  AR) but not all characteristics.<sup>13</sup> These results are in agreement with other studies suggesting the presence of a lipophilic pocket in the  $A_1$  and  $A_3$  AR binding sites that is filled by moderately sized cycloalkyl or other hydrophobic rings at the  $N^6$  position of adenosine derivatives.<sup>8</sup> Data described herein demonstrated an important commonality between the SAR of the  $N^6$  cycloalkyl ring seen within this study of adenine derivatives and previous work<sup>9,12</sup> on  $A_1$  AR antagonists. The dependence of  $A_3$  AR affinity on the ring size seemed to mirror the SAR profile for a class of  $N^6$ -cycloalkyl-9-benzyl-2-phenyladenines reported to antagonize the  $A_1$  receptor by Lucacchini and co-workers.<sup>9</sup> Within that study it was shown that the  $N^6$ -cycloalkyl ring size was optimized at either cyclohexyl or cycloheptyl rings, while the cyclooctyl analogues showed a marked decrease in affinity. These findings might represent a common feature of the ligand–receptor interaction characteristic of both receptor subtypes. Curiously, the  $N^6$ -(2-*endo*-norbornyl) substituent led to high  $A_3$  AR affinity and selectivity in the present series of 2-substituted adenines, while it led to high affinity and selectivity at the  $A_1$  AR subtype for adenines not substituted at the 2 position<sup>14</sup> and for adenosine derivatives.<sup>22</sup> Integration of novel 2 position side-chains provided an initial SAR. The discovery of the seemingly favorable effect on the  $A_3$  AR of inclusion of either phenyl or 4-(dimethylamino)phenyl moieties at the 2 position represents a new finding.

On the theme of dedifferentiation by reversine (**2**), ARs are known to have effects on growth and proliferation; thus, we considered a possible connection between dedifferentiation ascribed to **2** and its activity at one or more of the ARs. Each of the four ARs is coupled to mitogen-activated protein kinases (MAPK).<sup>17</sup> Specific activation of one receptor subtype versus another has been shown to initiate a myriad of biological events, including alterations to the cell cycle.<sup>17</sup> For example, expression of the  $A_1$  receptor within ob17 preadipocytes stimulated differentiation while slowing proliferation relative to unaltered cells.<sup>24</sup> Stimulation of the  $A_{2B}$  receptors by known agonists 2-chloroadenosine and 5'-(*N*-methylcarboxamido)adenosine was shown to down-



regulate DNA synthesis and slow cellular proliferation.<sup>25</sup> Treatment of rat lymphoma cells with adenosine and the specific A<sub>3</sub> agonist IB-MECA was shown to down-regulate DNA synthesis, proliferation, and telomeric signaling.<sup>26</sup> A<sub>3</sub> AR agonists appear to have a net cytostatic effect triggered through activation of the ERK 1/2 pathway.<sup>17</sup> Even from this small sampling of studies it is apparent that the function of the ARs in cell signaling is complex and still in the process of being elucidated.

A relationship between the antagonistic effects on the A<sub>3</sub> AR demonstrated by **2** and the observed cellular dedifferentiation reported by Chen et al.<sup>18</sup> could not be demonstrated in the present study. The analogues of **2** reported in the present study might be of use in further delineating the role that the ARs play during the dedifferentiation process; however, we were unsuccessful in our attempts to recreate an appreciable degree of myoblast dedifferentiation with various AR antagonists, including **2**. Obviously, further study is needed to advance this series of compounds as modulators of the function of the ARs and within the delineation of the individual roles of the ARs on the cell cycle, including dedifferentiation. However, A<sub>3</sub> adenosine antagonists are not to be considered general dedifferentiation reagents. Even the preliminary information about the SAR of reversine congeners presented by Chen et al.<sup>18</sup> did not appear to match the structural requirements for binding to the A<sub>3</sub> receptor.

In conclusion, on the basis of the relatively simple 2,6-disubstituted purine template, we have designed highly selective A<sub>3</sub> AR antagonists reaching high affinity. Among the most potent and selective A<sub>3</sub> AR antagonists in comparison to A<sub>1</sub> and A<sub>2A</sub> ARs were compounds **12**, **19**, and **22**. Compound **19** and other analogues were also demonstrated to be nearly inactive at the A<sub>2B</sub> AR. It will now be worthwhile to examine such antagonists as potential antiglaucoma agents, although the species selectivity of these antagonists will limit the experimental models that may be used.<sup>32</sup> Although reversine was previously identified as a dedifferentiating agent and we have presently shown it to be a moderately potent AR antagonist, we were unable to demonstrate a link between AR antagonism and dedifferentiation.

## Experimental Section

**Reagents and Instrumentation.** 6-Chloro-2-fluoropurine (**3**) was purchased from Oakwood Products, Inc. [<sup>125</sup>I]-N<sup>6</sup>-(4-Amino-3-iodobenzyl)adenosine-5'-N-methyluronamide (I-AB-MECA, 2000 Ci/mmol), [<sup>3</sup>H]DPCPX (80–130 Ci/mmol), and [<sup>3</sup>H]cyclic-AMP (40 Ci/mmol) were purchased from Amersham Biosciences Corp. (Piscataway, NJ). [<sup>3</sup>H]ZM241385 (4-2-[7-amino-2-(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-yl-amino]-ethylphenol; 17 Ci/mmol) was purchased from Tocris Cookson Inc. (Ellisville MO). All other reagents and solvents were purchased from Sigma-Aldrich. Selected intermediates and products were analyzed on an Agilent 1100 series LC/MSD SL using a Zorbax Eclipse XDB-C8 reverse phase column (4.6 × 150 mm, 5 μm). High-resolution mass spectroscopy measurements were performed on a Micromass/Waters LCT Premier Electrospray TOF mass spectrometer. <sup>1</sup>H NMR data was recorded on a Varian Gemini300, and spectra were recorded in DMSO-*d*<sub>6</sub> and/or CDCl<sub>3</sub> and were referenced to the residual solvent peaks at 2.50 and 7.26, respectively. Elemental analyses (C, H, N) were performed by Atlantic Microlabs, Inc. (Norcross, GA).

**General Procedure for the Preparation of 2 and 4–21.** Diisopropylethylamine (1.2 equiv) and the appropriate primary amine for N<sup>6</sup> substitution (0.9 equiv) were added to a solution of 6-chloro-2-fluoropurine (**3**) (1 equiv) in *n*-butanol (2–4 mL), and the mixture was heated for 15–24 h at 80 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure to yield a yellow solid. An aliquot was removed for LC–MS analysis. The remaining solid was transferred to a sealed reaction vessel containing EtOH (2–4 mL) and the appropriate amine (2 equiv) for substitution at the 2 position, where the mixture was heated for 48 h at 110 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure. The resulting solid was purified via column chromatography (EtOAc) to yield compounds **2** and **4–21** as white or off-white solids.

**2-(4-Morpholinoanilino)-6-(cyclohexylamino)purine (2):** yield 63 mg (55%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–10 min, linear gradient from 10% to 30% CH<sub>3</sub>CN; 10–15 min, linear gradient from 30% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 14.6 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.11–1.43 (m, 6H), 1.58–1.80 (m, 3H), 1.82–1.99 (m, 2H), 2.90–3.28 (m, 4H), 3.71–3.78 (m, 4H), 4.08 (bs, 1H), 6.81 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.02 (bs, 1H), 7.63 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.72 (s, 1H), 8.51 (s, 1H); TOFMS *m/z* (M + H<sup>+</sup>) 394.2355 (calculated for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup>) 394.2350.

**2-(4-Morpholinoanilino)-6-(ethylamino)purine (4):** yield 93 mg (95%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 3.1 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.29 (t, *J*<sub>HH</sub> = 7.2 Hz, 3H), 3.08–3.11 (m, 4H), 3.23–2.29 (m, 2H), 3.63 (bs, 1H), 3.81–3.84 (m, 4H), 6.93 (d, *J*<sub>HH</sub> = 8.4 Hz, 2H), 7.76 (d, *J*<sub>HH</sub> = 8.7 Hz, 2H), 7.82 (s, 1H), 7.39 (bs, 1H), 8.60 (s, 1H); TOFMS *m/z* 340.1886 (M + H<sup>+</sup>) (calculated for C<sub>17</sub>H<sub>22</sub>N<sub>7</sub>O<sup>+</sup>) 340.1880.

**2-(4-Morpholinoanilino)-6-(cyclopropylamino)purine (5):** yield 58 mg (57%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–5 min, linear gradient from 25% to 50% CH<sub>3</sub>CN; 5–10 min, linear gradient from 50% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 4.7 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 0.45–0.50 (m, 2H), 0.61–0.68 (m, 2H), 0.70–0.78 (m, 1H), 2.97–3.08 (m, 4H), 3.69–3.76 (m, 4H), 7.48 (bs, 1H), 7.75 (d, *J*<sub>HH</sub> = 9.6 Hz, 2H), 7.92 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 8.35 (s, 1H), 9.18 (s, 1H); TOFMS *m/z* 352.1885 (M + H<sup>+</sup>) (calculated for C<sub>18</sub>H<sub>22</sub>N<sub>7</sub>O<sup>+</sup>) 352.1880.

**2-(4-Morpholinoanilino)-6-(cyclobutylamino)purine (6):** yield 64 mg (60%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 2.9 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.57–1.74 (m, 2H), 2.06–2.16 (m, 2H), 2.20–2.32 (m, 3H), 2.99–3.02 (m, 4H), 3.71–3.74 (m, 4H), 4.65 (bs, 1H), 6.85 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.58 (bs, 1H), 7.66 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.75 (s, 1H), 8.45 (s, 1H); TOFMS *m/z* 366.2042 (M + H<sup>+</sup>) (calculated for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>O<sup>+</sup>) 366.2037.

**2-(4-Morpholinoanilino)-6-(cyclopentylamino)purine (7):** yield 77 mg (70%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–12 min, linear gradient from 5% to 25% CH<sub>3</sub>CN; 12–20 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 16.5 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.42–1.77 (m, 6H), 1.81–2.03 (m, 3H), 2.97–3.06 (m, 4H), 3.70–3.75 (m, 4H), 4.05 (bs, 1H), 6.83 (d, *J*<sub>HH</sub> = 9.3 Hz, 2H), 7.26 (bs, 1H), 7.67 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 8.45 (s, 1H), 9.04 (s, 1H); TOFMS *m/z* 380.2199 (M + H<sup>+</sup>) (calculated for C<sub>20</sub>H<sub>26</sub>N<sub>7</sub>O<sup>+</sup>) 380.2193.

**2-(4-Morpholinoanilino)-6-(cycloheptylamino)purine (8):** yield 33 mg (28%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–5 min, linear gradient from 10% to 50% CH<sub>3</sub>CN; 5–20 min, linear gradient

from 50% to 70% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 8.6 min; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.46–1.72 (m, 10H), 1.87–1.98 (m, 3H), 2.98–3.01 (m, 4H), 3.72–3.75 (m, 4H), 4.22 (bs, 1H), 6.83 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.25 (bs, 1H), 7.66 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.73 (s, 1H), 8.45 (s, 1H); TOFMS *m/z* 408.2512 (M + H<sup>+</sup>) (calculated for C<sub>22</sub>H<sub>30</sub>N<sub>7</sub>O<sup>+</sup>) 408.2506.

**2-(4-Morpholinoanilino)-6-(cyclooctylamino)purine (9):** yield 87 mg (71%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 30% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 8.5 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 0.78–0.92 (m, 1H), 1.08–1.35 (m, 8H), 1.45–1.88 (m, 6H), 2.95–3.06 (m, 4H), 3.67–3.79 (m, 4H), 4.38 (bs, 1H), 6.83 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.19 (bs, 1H), 7.65–7.72 (m, 3H), 8.48 (s, 1H); TOFMS *m/z* 422.2668 (M + H<sup>+</sup>) (calculated for C<sub>23</sub>H<sub>32</sub>N<sub>7</sub>O<sup>+</sup>) 422.2662.

**2-(4-Morpholinoanilino)-6-[(2-*endo*-norbornyl)amino]-purine (10):** yield 32 mg (27%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.77–0.95 (m, 2H), 1.18–1.78 (m, 8H), 2.50–2.66 (m, 2H), 3.11 (dd, *J*<sub>HH</sub> = 4.8, 4.5 Hz, 4H), 3.86 (dd, *J*<sub>HH</sub> = 4.8, 4.5 Hz, 4H), 4.38 (bs, 1H), 5.70 (bs, 1H), 6.68 (s, 1H), 6.90 (d, *J*<sub>HH</sub> = 8.7 Hz, 2H), 7.45 (d, *J*<sub>HH</sub> = 8.7 Hz, 2H); TOFMS *m/z* 406.2369 (M + H<sup>+</sup>) (calculated for C<sub>22</sub>H<sub>28</sub>N<sub>7</sub>O<sup>+</sup>) 406.2355.

**2-(Ethylamino)-6-(cyclohexylamino)purine (11):** yield 72 mg (95%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–12 min, linear gradient from 5% to 30% CH<sub>3</sub>CN; 12–20 min, linear gradient from 30% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 16.6 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.09 (t, *J*<sub>HH</sub> = 7.2 Hz, 3H), 1.12–1.36 (m, 6H), 1.58–1.63 (m, 1H), 1.65–1.76 (m, 2H), 1.83–1.91 (m, 2H), 3.18–3.27 (m, 2H), 3.42 (bs, 1H), 4.02 (bs, 1H), 7.65 (s, 1H), 6.81 (bs, 1H); TOFMS *m/z* 261.1827 (M + H<sup>+</sup>) (calculated for C<sub>13</sub>H<sub>21</sub>N<sub>6</sub><sup>+</sup>) 261.1822.

**2-(Phenylamino)-6-(cyclohexylamino)purine (12):** yield 43 mg (60%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.20–1.50 (m, 6H), 1.60–1.85 (m, 4H), 2.05–2.20 (m, 2H), 4.10 (bs, 1H), 5.60 (bs, 1H), 6.95 (s, 1H), 7.06 (t, *J*<sub>HH</sub> = 7.8 Hz, 1H), 7.33 (t, *J*<sub>HH</sub> = 7.8 Hz, 2H), 7.56 (d, *J*<sub>HH</sub> = 7.8 Hz, 2H); TOFMS *m/z* 309.1823 (M + H<sup>+</sup>) (calculated for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub><sup>+</sup>) 309.1828.

**2-(Benzylamino)-6-(cyclohexylamino)purine (13):** yield 35 mg (47%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.10–1.50 (m, 6H), 1.56–1.82 (m, 4H), 2.00–2.12 (m, 2H), 4.66 (d, *J*<sub>HH</sub> = 6.0 Hz, 2H), 4.82 (bs, 1H), 5.58 (bs, 1H), 7.09 (s, 1H), 7.22–7.40 (m, 5H); TOFMS *m/z* 323.1975 (M + H<sup>+</sup>) (calculated for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup>) 323.1984.

**2-(2-Phenethylamino)-6-(cyclohexylamino)purine (14):** yield 51 mg (65%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.10–1.50 (m, 6H), 1.60–1.85 (m, 4H), 2.04–2.15 (m, 2H), 2.97 (t, *J*<sub>HH</sub> = 6.9 Hz, 2H), 3.69 (m, *J*<sub>HH</sub> = 6.9, 6.0 Hz, 2H), 4.88 (bs, 1H), 5.50 (bs, 1H), 7.22–7.36 (m, 5H), 7.40 (s, 1H); TOFMS *m/z* 337.2126 (M + H<sup>+</sup>) (calculated for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub><sup>+</sup>) 337.2141

**2-(2-Naphthylamino)-6-(cyclohexylamino)purine (15):** yield 37 mg (45%); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.10–1.50 (m, 6H), 1.60–1.85 (m, 4H), 1.94–2.04 (m, 2H), 4.20 (bs, 1H), 7.28 (t, *J*<sub>HH</sub> = 8.1 Hz, 1H), 7.42 (t, *J*<sub>HH</sub> = 8.1 Hz, 1H), 7.65–7.70 (m, 4H), 7.85 (s, 1H), 8.53 (s, 1H), 9.05 (bs, 1H); TOFMS *m/z* 359.1994 (M + H<sup>+</sup>) (calculated for C<sub>21</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup>) 359.1984.

**2-(Biphen-1-ylamino)-6-(cyclohexylamino)purine (16):** yield 46 mg (41%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–12 min, linear gradient from 5% to 25% CH<sub>3</sub>CN; 12–15 min, linear gradient from 25% to 60% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 12.4 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.15–1.39 (m, 6H), 1.59–1.78 (m, 3H), 1.92–2.01 (m, 2H), 3.71 (bs, 1H), 7.31–7.33 (m, 1H), 7.42–7.47 (m, 3H), 7.56–7.66 (m, 4H), 7.79 (s, 1H), 8.15 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 9.42 (s, 1H); TOFMS *m/z* 385.2141 (M + H<sup>+</sup>) (calculated for C<sub>23</sub>H<sub>25</sub>N<sub>6</sub><sup>+</sup>) 385.2135.

**2-(4-Piperidinoanilino)-6-(cyclohexylamino)purine (17):** yield 25 mg (27%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.10–1.80 (m, 16H), 2.00–2.20 (m, 2H), 3.00–3.25 (m, 4H), 4.13 (bs, 1H), 5.70 (bs, 1H), 6.68 (s, 1H), 6.92 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.41 (d, *J*<sub>HH</sub> = 9.0

Hz, 2H); TOFMS *m/z* 392.2576 (M + H<sup>+</sup>) (calculated for C<sub>22</sub>H<sub>30</sub>N<sub>7</sub><sup>+</sup>) 392.2563.

**2-[[4-(Dimethylamino)phenyl]amino]-6-(cyclohexylamino)purine (18):** yield 20 mg (25%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.10–1.50 (m, 6H), 1.60–1.85 (m, 4H), 2.04–2.14 (m, 2H), 2.92 (s, 6H), 4.10 (bs, 1H), 5.53 (bs, 1H), 6.56 (s, 1H), 6.74 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H), 7.38 (d, *J*<sub>HH</sub> = 9.0 Hz, 2H); TOFMS *m/z* 352.2247 (M + H<sup>+</sup>) (calculated for C<sub>19</sub>H<sub>26</sub>N<sub>7</sub><sup>+</sup>) 352.2250

**2-(Phenylamino)-6-(cycloheptylamino)purine (19):** yield 36 mg (48%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.40–1.80 (m, 12H), 2.00–2.20 (m, 2H), 4.30 (bs, 1H), 5.60 (bs, 1H), 6.90 (s, 1H), 7.05 (t, *J*<sub>HH</sub> = 7.5 Hz, 1H), 7.32 (t, *J*<sub>HH</sub> = 7.5 Hz, 2H), 7.57 (d, *J*<sub>HH</sub> = 7.5 Hz, 2H); TOFMS *m/z* 323.1982 (M + H<sup>+</sup>) (calculated for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup>) 323.1984.

**2-(Phenylamino)-6-(cyclooctylamino)purine (20):** yield 78 mg (80%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 30% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 10.1 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.49–1.87 (m, 15H), 3.22–3.44 (bs, 1H), 7.17–7.22 (m, 3H), 7.79–7.84 (m, 3H), 8.02 (s, 1H), 8.75 (s, 1H); TOFMS *m/z* 337.2141 (M + H<sup>+</sup>) (calculated for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub><sup>+</sup>) 337.2135.

**2-(Phenylamino)-6-(2-*endo*-norbornylamino)purine (21):** yield 31 mg (42%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.77–0.95 (m, 2H), 1.18–1.78 (m, 8H), 2.50–2.66 (m, 2H), 4.38 (bs, 1H), 5.80 (bs, 1H), 6.90 (s, 1H), 7.07 (t, *J*<sub>HH</sub> = 7.5 Hz, 1H), 7.21 (dd, *J*<sub>HH</sub> = 7.8, 7.5 Hz, 2H), 7.54 (d, *J*<sub>HH</sub> = 7.8 Hz, 2H); TOFMS *m/z* 321.1828 (M + H<sup>+</sup>) (calculated for C<sub>18</sub>H<sub>21</sub>N<sub>6</sub><sup>+</sup>) 321.1828.

**2-Phenoxy-6-(cyclohexylamino)purine (22).** Cyclohexylamine (30 μL, 0.26 mmol) and diisopropylethylamine (61 μL, 0.35 mmol) were added to a solution of 6-chloro-2-fluoropurine (**3**) (50 mg, 0.29 mmol) in *n*-butanol (2 mL), and the mixture heated for 15 h at 80 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure to yield a yellow solid. An aliquot was removed for LC–MS analysis. The remaining solid was transferred to a sealed reaction vessel with EtOH (5 mL), and phenol (48 mg, 0.5 mmol) and potassium *tert*-butoxide (47 mg, 0.42 mmol) were added. The mixture was heated for 48 h at 110 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure. The resulting solid was purified via column chromatography (EtOAc) to yield **22** as a white powder: yield 6 mg (8%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 7.3 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.14–1.46 (6H), 1.67–1.98 (m, 5H), 4.13 (bs, 1H), 7.22–7.30 (m, 3H), 7.46–7.51 (m, 2H), 7.61 (bs, 1H), 7.99 (s, 1H); TOFMS *m/z* 310.1668 (M + H<sup>+</sup>) (calculated for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup>) 310.1662.

**2-Phenoxy-6-(2-*endo*-norbornylamino)purine (23).** 2-Aminonorborane hydrochloride (46 mg, 0.31 mmol) and diisopropylethylamine (73 μL, 0.42 mmol) were added to a solution of 6-chloro-2-fluoropurine (**3**) (60 mg, 0.35 mmol) in *n*-butanol (2 mL), and the mixture was heated for 15 h at 80 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure to yield a yellow solid. An aliquot was removed for LC–MS analysis. The remaining solid was transferred to a sealed reaction vessel with EtOH (5 mL), and phenol (66 mg, 0.70 mmol) and potassium *tert*-butoxide (79 mg, 0.70 mmol) were added. The mixture was heated for 48 h at 110 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure. The resulting solid was purified via column chromatography (EtOAc) to yield **23** as a white powder: yield 4.0 mg (4.3%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC–MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 10.2 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 1.22–1.62 (m, 10H), 1.80–1.95 (m, 1H), 4.16 (bs, 1H), 7.13–7.20 (m, 3H), 7.36–7.41 (m, 2H), 7.77 (bs, 1H), 7.92 (s, 1H); TOFMS *m/z* (M + H<sup>+</sup>) 322.1668 (calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup>) 322.1662.



**2-(Phenylthio)-6-(cyclohexylamino)purine (24).** Cyclohexylamine (30  $\mu$ L, 0.26 mmol) and diisopropylethylamine (61  $\mu$ L, 0.35 mmol) were added to a solution of 6-chloro-2-fluoropurine (**3**) (50 mg, 0.29 mmol) in *n*-butanol (2 mL), and the mixture was heated for 15 h at 80 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure to yield a yellow solid. An aliquot was removed for LC-MS analysis. The remaining solid was transferred to a sealed reaction vessel, where EtOH (2 mL) and thiophenol (51  $\mu$ L, 0.5 mmol) were added, and the mixture was heated for 48 h at 110 °C. The solution was allowed to cool, and the solvent was removed under reduced pressure. The resulting solid was purified via column chromatography (EtOAc) to yield **24** as a white powder: yield 43 mg (63%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC-MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–15 min, linear gradient from 25% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 9.6 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.12–1.30 (m, 6H), 1.50–1.89 (m, 5H), 3.66 (bs, 1H), 7.41–7.45 (m, 3H), 7.58–7.62 (m, 3H), 7.93 (s, 1H); TOFMS *m/z* 326.1439 (M + H<sup>+</sup>) (calculated for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>S<sup>+</sup>) 326.1434.

**9-Methyl-2-(phenylamino)-6-(cyclohexylamino)purine (25).** **12** (17 mg, 0.06 mmol) was added to a slurry of potassium carbonate (9.7 mg, 0.07 mmol) in DMF (0.5 mL). The mixture was cooled to 0 °C, and methyl iodide (5.6  $\mu$ L, 0.09 mmol) was added. The reaction was allowed to stir for 1 h at 0 °C followed by the addition of water (1 mL) and EtOAc (1 mL). The mixture was extracted with EtOAc (3  $\times$  5 mL). The organic layers were collected and dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure to yield **25** as a white solid: yield 18 mg (95%); purity analysis was achieved by C<sub>8</sub> reversed-phase LC-MS using a linear gradient of H<sub>2</sub>O containing increasing amounts of CH<sub>3</sub>CN (0–5 min, linear gradient from 25% to 50% CH<sub>3</sub>CN; 5–10 min, linear gradient from 50% to 90% CH<sub>3</sub>CN at a flow rate of 1 mL/min; *t*<sub>R</sub> 9.8 min); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.12–1.81 (m, 6H), 1.24–1.43 (m, 3H), 1.91–1.99 (m, 2H), 3.64 (s, 3H), 4.10 (bs, 1H), 7.19–7.24 (m, 3H), 7.86 (d, *J*<sub>HH</sub> = 8.4 Hz, 2H), 7.96 (s, 1H); TOFMS *m/z* 323.1984 (M + H<sup>+</sup>) (calculated for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup>) 323.1979.

**9-Methyl-2-(phenylamino)-6-(cycloheptylamino)purine (26).** **19** (20 mg, 0.062 mmol) was added to a slurry of potassium carbonate (10.3 mg, 0.075 mmol) in DMF (0.5 mL). The mixture was cooled to 0 °C, and methyl iodide (5.8  $\mu$ L, 0.093 mmol) was added. The reaction was allowed to stir for 1 h at 0 °C followed by the addition of water (1 mL) and EtOAc (1 mL). The mixture was extracted with EtOAc (3  $\times$  5 mL). The organic layers were collected and dried (Na<sub>2</sub>SO<sub>4</sub>), and solvent was removed under reduced pressure to yield **26** as a white solid: yield 18 mg (86%); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.40–1.80 (m, 12H), 2.00–2.20 (m, 2H), 3.73 (s, 3H), 4.30 (bs, 1H), 6.97 (t, *J*<sub>HH</sub> = 7.5 Hz, 1H), 7.31 (t, *J*<sub>HH</sub> = 7.5 Hz, 2H), 7.72 (d, *J*<sub>HH</sub> = 7.5 Hz, 2H), 8.02 (s, 1H); TOFMS *m/z* 337.2148 (M + H<sup>+</sup>) (calculated for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub><sup>+</sup>) 337.2141.

**Cell Culture and Membrane Preparation.** CHO (Chinese hamster ovary) cells expressing the recombinant human ARs were cultured in Dulbecco's modified Eagle medium (DMEM) and F12 (1:1) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100  $\mu$ g/mL streptomycin, and 2  $\mu$ mol/mL glutamine. After harvesting, cells were homogenized and suspended. Cells were then centrifuged at 500g for 10 min, and the pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl<sub>2</sub>. The suspension was homogenized and was then recentrifuged at 20 000g for 20 min at 4 °C. The resultant pellets were resuspended in Tris buffer, and the suspension was stored at –80 °C until the binding experiments. The protein concentration was measured using the Bradford assay.<sup>27</sup>

**Radioligand Binding Assays.** Each tube in the A<sub>3</sub> AR competitive binding assay<sup>20</sup> contained 100  $\mu$ L of membrane suspension (20  $\mu$ g of protein), 50  $\mu$ L of [<sup>125</sup>I]-4-amino-3-iodobenzyladenosine-5'-*N*-methyluronamide (0.5 nM), and 50  $\mu$ L of increasing concentrations of the test ligands in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl<sub>2</sub> and 1 mM EDTA. Nonspecific binding was determined using 10 mM 5'-

*N*-ethylcarboxamidoadenosine in the buffer. The mixtures were incubated at 25 °C for 60 min. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandell, Gaithersburg, MD). Filters were washed three times with 9 mL of ice-cold buffer. Radioactivity was determined using a Beckman  $\gamma$ -counter, and the percent inhibition was calculated.

The antagonists [<sup>3</sup>H]DPCPX (0.5 nM) and [<sup>3</sup>H]ZM241,385 (2 nM) were used as radioligands for A<sub>1</sub> and A<sub>2A</sub> ARs, respectively. Each assay tube used to measure competitive binding for human A<sub>1</sub> and A<sub>2A</sub> ARs contained 100  $\mu$ L of membrane suspension (20  $\mu$ g of protein), 50  $\mu$ L of radioligand, and 50  $\mu$ L of 10  $\mu$ M test ligand in the Tris-HCl buffer. Nonspecific binding was measured using 10  $\mu$ M NECA in the buffer. Each assay was incubated at 25 °C for 60 min and was terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester. Filters were washed three times with ice-cold buffer and placed in scintillation vials. Each vial also contained 5 mL of Hydrofluor scintillation buffer. All compounds that gave more than 60% inhibition at 10  $\mu$ M for either A<sub>1</sub> or A<sub>2A</sub> ARs were also tested using a full concentration curve between 10<sup>–9</sup> and 10<sup>–5</sup> M in order to determine a *K*<sub>i</sub> value.

**Cyclic AMP Accumulation Assay.** Intracellular cyclic AMP levels were measured with a competitive protein binding method.<sup>28,29</sup> CHO cells expressing the recombinant human A<sub>2B</sub> AR or A<sub>3</sub> AR were harvested by trypsinization. After centrifugation and resuspension in medium, cells were plated in 24-well plates in 0.5 mL of medium. After 24 h the medium was removed, and cells were washed three times with 1 mL of DMEM containing 50 mM HEPES, pH 7.4. Cells were then treated with the appropriate agonist, NECA (100 nM) for the A<sub>2B</sub> AR or variable concentrations of Cl-IB-MECA for the A<sub>3</sub> AR and/or adenine derivatives in the presence of rolipram (10  $\mu$ M). For the A<sub>2B</sub> AR, incubation was carried out for 1 h. For the A<sub>3</sub> AR, after an initial incubation of 45 min, forskolin (10  $\mu$ M) was added to the medium, and incubation was continued for an additional 15 min. The reaction was terminated by removing the supernatant, and cells were lysed upon the addition of 200  $\mu$ L of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored at –20 °C. For determination of cyclic AMP production, protein kinase A (PKA) was incubated with [<sup>3</sup>H]cyclic AMP (2 nM) in K<sub>2</sub>HPO<sub>4</sub>/EDTA buffer (K<sub>2</sub>HPO<sub>4</sub>, 150 mM; EDTA, 10 mM), 20  $\mu$ L of the cell lysate, and 30  $\mu$ L 0.1M HCl or 50  $\mu$ L of cyclic AMP solution (0–16 pmol/200  $\mu$ L for standard curve). Bound radioactivity was separated by rapid filtration through Whatman GF/C filters and washed once with cold buffer. Bound radioactivity was measured by liquid scintillation spectrometry. A Schild constant (*K*<sub>B</sub>) was calculated as described using the equation.<sup>30</sup>

**Statistical Analysis.** Binding and functional parameters were calculated using Prism 5.0 software (GraphPAD, San Diego, CA). IC<sub>50</sub> values obtained from competition curves were converted to *K*<sub>i</sub> values using the Cheng-Prusoff equation.<sup>31</sup> Data were expressed as the mean  $\pm$  standard error.

**Studies of Cellular Differentiation.** Mouse C2C12 myogenic cells (ATCC, Manassas, VA) were plated in 6-well plates in growth medium (DMEM with 10% fetal bovine serum), and after overnight incubation (during which time cells attach to the bottom of the plate), 5  $\mu$ M adenine derivative or other AR antagonists were added. After 4 days, medium containing the antagonists was removed and replaced with differentiating medium containing 50  $\mu$ g/mL ascorbic acid-2-phosphate, 0.1  $\mu$ M dexamethasone, and 10 mM  $\beta$ -glycerophosphate in 10% fetal bovine serum (to direct the cells from myogenic differentiation to osteogenic). The culture was maintained for an additional 4–7 days. Cells were stained for alkaline phosphatase activity using a semiquantitative method ("Leukocyte" Alkaline Phosphatase kit, Procedure No. 85, Sigma), observed using a Nikon microscope, and compared with control cells subjected to the same treatment except not exposed to differentiating medium or AR antagonist.

**Acknowledgment.** The authors thank Dr. John Lloyd and Dr. Sonya Hess (NIDDK) for assistance in obtaining the HRMS data.

**Supporting Information Available:** Characterization of adenine derivatives. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. M. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. *Pharmacol. Rev.* **2001**, *53*, 527–552.
- Yao, L.; Burbiel, J. C.; Maass, A.; Müller, C. E. Adenosine receptor agonists: From basic medicinal chemistry to clinical development. *Expert Opin. Emerging Drugs* **2003**, *8*, 537–576.
- Tchilibon, S.; Joshi, B. V.; Kim, S.-Y.; Duong, H. T.; Gao, Z.-G.; Jacobson, K. A. (*N*)-Methanocarba 2,*N*<sup>6</sup>-disubstituted adenine nucleosides as highly potent and selective A<sub>3</sub> adenosine receptor agonists. *J. Med. Chem.* **2005**, *48*, 1745–1758, and references therein.
- Mogensen, J. P.; Roberts, S. M.; Bowler, A. N.; Thomsen, C.; Knutsen, L. J. The synthesis of new adenosine A<sub>3</sub> selective ligands containing bioisosteric isoxazoles. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1767–1770.
- Lee, K.; Ravi, R. G.; Ji, X.-d.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (*N*) methanocarba-nucleosides as adenosine receptor agonists: Independent 5'-uronamide and 2'-deoxy modifications. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1333–1337.
- Ohno, M.; Gao, Z. G.; Van Rompaey, P.; Tchilibon, S.; Kim, S. K.; Harris, B. A.; Blaustein, J.; Gross, A. S.; Duong, H. T.; Van Calenbergh, S.; Jacobson, K. A. Modulation of adenosine receptor affinity and intrinsic efficacy in nucleosides substituted at the 2-position. *Bioorg. Med. Chem.* **2004**, *12*, 2995–3007.
- Tchilibon, S.; Kim, S. K.; Gao, Z. G.; Harris, B. A.; Blaustein, J.; Gross, A. S.; Melman, N.; Jacobson, K. A. Exploring distal regions of the A<sub>3</sub> adenosine receptor binding site: Sterically constrained *N*<sup>6</sup>-(2-phenylethyl)adenosine derivatives as potent ligands. *Bioorg. Med. Chem. Lett.* **2004**, *12*, 2021–2034.
- Gao, Z.-G.; Blaustein, J. B.; Gross, A. S.; Melman, N.; Jacobson, K. A. *N*<sup>6</sup>-Substituted adenosine derivatives: Selectivity, efficacy and species differences at A<sub>3</sub> adenosine receptors. *Biochem. Pharmacol.* **2003**, *65*, 1675–1684.
- Biagi, G.; Giorgi, I.; Livi, O.; Nardi, A.; Pacchini, F.; Scartoni, V.; Lucacchini, A. *N*<sup>6</sup>-Cycloalkyl-2-phenyl-3-deaza-8-aza-adenines: A new class of A<sub>1</sub> adenosine receptor ligands. A comparison with the corresponding adenines and 8-azaadenines. *Eur. J. Med. Chem.* **2003**, *38*, 983–990.
- Volpini, R.; Costanzi, S.; Lambertucci, C.; Taffi, S.; Vittori, S.; Klotz, K. N.; Cristalli, G. *N*<sup>6</sup>-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A<sub>3</sub> receptor and a starting point for searching A<sub>2b</sub> ligands. *J. Med. Chem.* **2002**, *45*, 3271.
- Klotz, K.-N.; Kachler, S.; Lambertucci, C.; Vittori, S.; Volpini, R.; Cristalli, G. 9-Ethyladenine derivatives as adenosine receptor antagonist: 2- And 8-substitution results in distinct selectivities. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2003**, *367*, 629–634.
- Thompson, R. D.; Secunda, S.; Daly, J. W.; Olsson, R. A. *N*<sup>6</sup>,9-disubstituted adenines: Potent, selective antagonists at the A<sub>1</sub> adenosine receptor. *J. Med. Chem.* **1991**, *34*, 2877–82.
- Jacobson, K. A.; Siddiqi, S. M.; Olah, M. E.; Ji, X. D.; Melman, N.; Bellamkonda, K.; Meshulam, Y.; Stiles, G.L.; Kim, H. O. Structure–activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A<sub>3</sub> adenosine receptors. *J. Med. Chem.* **1995**, *38*, 1720–35.
- Martin, P. L.; Wysocki, R. J., Jr.; Barrett, R. J.; May, J. M.; Linden, J. Characterization of 8-(*N*-methylisopropylamino)-*N*<sup>6</sup>-(5'-endohydroxy-endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, nonxanthine antagonist of A<sub>1</sub> adenosine receptors. *J. Pharmacol. Exp. Ther.* **1996**, *276*, 490–9.
- Martin, P. L.; Ueeda, M.; Olsson, R. A. 2-Phenylethoxy-9-methyladenine: An adenosine receptor antagonist that discriminates between A<sub>2</sub> adenosine receptors in the aorta and the coronary vessels from the guinea pig. *J. Pharmacol. Exp. Ther.* **1993**, *265*, 248–53.
- Laufer, S. A.; Domeyer, D. M.; Scior, T. R.; Albrecht, W.; Hauser, D. R. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. *J. Med. Chem.* **2005**, *48*, 710–22.
- Schulte, G.; Fredholm, B. B. Signaling from adenosine receptors to mitogen-activated protein kinases. *Cell. Signal.* **2003**, *15*, 813–827.
- Chen, S.; Zhang, Q.; Wu, X.; Schultz, P. G.; Ding, S. Dedifferentiation of lineage-committed cells by a small molecule. *J. Am. Chem. Soc.* **2004**, *126*, 410–411.
- Ding, S.; Gray, N. S.; Wu, X.; Ding, Q.; Schultz, P. G. A combinatorial scaffold approach toward kinase-directed heterocycle libraries. *J. Am. Chem. Soc.* **2002**, *124*, 1594–1596.
- Olah, M. E.; Gallo-Rodriguez, C.; Jacobson, K. A.; Stiles, G. L. [<sup>125</sup>I]AB-MECA, a high affinity radioligand for the rat A<sub>3</sub> adenosine receptor. *Mol. Pharmacol.* **1994**, *45*, 978–982.
- Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes—Characterization of stably transfected receptors in CHO cells. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1998**, *357*, 1–9.
- Gao, Z. G., Mamedova, L., Chen, P., Jacobson, K. A. 2-Substituted adenosine derivatives: Affinity and efficacy at four subtypes of human adenosine receptors. *Biochem. Pharmacol.* **2004**, *68*, 1985–1993.
- Yasuda S. U.; Nagashima S.; Douyon E.; Benton R. E.; Woosley R. L.; Barbey J. T. Adenosine A<sub>1</sub>-receptor occupancy predicts A<sub>1</sub>-receptor antagonist effects of N-0861. *Clin Pharmacol Ther.* **1998**, *64*, 536–541.
- Tatsis-Kotsidis, I.; Erlanger, B. F. Initiation of a process of differentiation by stable transfection of ob17 preadipocytes with the cDNA of human A<sub>1</sub> adenosine receptor. *Biochem. Pharm.* **1999**, *58*, 167–170.
- Dubey, R. K.; Gillespie, D. G.; Shue, H.; Jackson, E. K. A<sub>2b</sub> Receptors mediate antimetogenesis in vascular smooth muscle cells. *Hypertension* **2000**, *35*, 267–272.
- Fishman, P.; Bar-Yehuda, S.; Ohana, G.; Pathak, S.; Wasserman, L.; Barer, F.; Multani, A. S. Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A<sub>3</sub> adenosine receptor. *Eur. J. Cancer* **2000**, *36*, 1452–1458.
- Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1990**, *189*, 231–234.
- Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for the rapid quantification of cAMP in cell-culture supernatants and body fluid. *Anal. Biochem.* **1990**, *189*, 231–234.
- Post, S. R.; Ostrom, R. S.; Insel, P. A. Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity. *Methods Mol. Biol.* **2000**, *126*, 363–374.
- Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. *Br. J. Pharmacol. Chemother.* **1959**, *14*, 48–58.
- Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant (*K*<sub>i</sub>) and the concentration of inhibitor which causes 50% inhibition (*I*<sub>50</sub>) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099–3108.
- Yang, H.; Avila, M. Y.; Peterson-Yantorno, K.; Coca-Prados, M.; Stone, R. A.; Jacobson, K. A.; Civan, M. M. The cross-species A<sub>3</sub> adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Curr. Eye Res.* **2005**, *30*, in press.
- Okamura, T.; Kurogi, Y.; Hashimoto, K.; Sato, S.; Nishikawa, H.; Kiryu, K.; Nagao, Y. Structure–activity relationships of adenosine A<sub>3</sub> receptor ligands: New potential therapy for the treatment of glaucoma. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3775–3779.
- Young, H. W.; Molina JG.; Dimina D.; Zhong H.; Jacobson M.; Chan LN.; Chan TS.; Lee JJ.; Blackburn MR. A<sub>3</sub> adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. *J. Immunol.* **2004**, *173*, 1380–9.

JM050221L